Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001339970-26-000033
Filing Date
2026-05-15
Accepted
2026-05-15 16:01:30
Documents
51
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atyr-20260331.htm   iXBRL 10-Q 1922366
2 EX-3.7 atyr-ex3_7.htm EX-3.7 15605
3 EX-10.1 atyr-ex10_1.htm EX-10.1 147147
4 EX-31.1 atyr-ex31_1.htm EX-31.1 12627
5 EX-31.2 atyr-ex31_2.htm EX-31.2 12619
6 EX-32.1 atyr-ex32_1.htm EX-32.1 8773
7 EX-32.2 atyr-ex32_2.htm EX-32.2 8405
  Complete submission text file 0001339970-26-000033.txt   7540350

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atyr-20260331.xsd EX-101.SCH 949187
55 EXTRACTED XBRL INSTANCE DOCUMENT atyr-20260331_htm.xml XML 1253487
Mailing Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121
Business Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121 8587318389
aTYR PHARMA INC (Filer) CIK: 0001339970 (see all company filings)

EIN.: 203435077 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37378 | Film No.: 26986695
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)